Aromatase inhibitors for breast cancer

被引：16

作者：

Briest, Susanne

Davidson, Nancy E. ^{[1
]}

机构：

[1] Johns Hopkins Sidney Kimmel Ctr Comprehens Canc, Baltimore, MD USA

[2] Univ Leipzig, Dept Gynecol & Obstet, Leipzig, Germany

来源：

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS | 2007年 / 8卷 / 03期

关键词：

breast cancer; endocrine treatment; estrogen receptor; aromatase inhibitor; postmenopausal; hormonal therapy;

D O I：

10.1007/s11154-007-9039-z

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Endocrine therapy is a mainstay for the many women who develop in situ or invasive steroid receptor-positive breast cancer. The use of tamoxifen has reduced mortality in such women. Recently estrogen deprivation strategies have come under scrutiny. Here the use of aromatase inhibitors for treatment of postmenopausal endocrine-responsive breast cancer in the metastatic, adjuvant, and preoperative settings is reviewed.

引用

页码：215 / 228

页数：14

共 84 条

[1]

Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0

[2] Endocrine-responsive breast cancer and strategies for combating resistance [J].

Ali, S ;

Coombes, RC .

NATURE REVIEWS CANCER, 2002, 2 (02) :101-+

[3] Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database [J].

Anderson, WF ;

Chatterjee, N ;

Ershler, WB ;

Brawley, OW .

BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 (01) :27-36

[4] The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients' [J].

Atalay, G ;

Dirix, L ;

Biganzoli, L ;

Beex, L ;

Nooij, M ;

Cameron, D ;

Lohrisch, C ;

Cufer, T ;

Lobelle, JP ;

Mattiaci, MR ;

Piccart, M ;

Paridaens, R .

ANNALS OF ONCOLOGY, 2004, 15 (02) :211-217

[5]

Baum M, 2002, LANCET, V359, P2131

[6]

BERNARDI A, 2002, P AN M AM SOC CLIN, V21, P217

[7] Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial [J].

Boccardo, F. ;

Rubagotti, A. ;

Guglielmini, P. ;

Fini, A. ;

Paladini, G. ;

Mesiti, M. ;

Rinaldini, M. ;

Scali, S. ;

Porpiglia, M. ;

Benedetto, C. ;

Restuccia, N. ;

Buzzi, F. ;

Franchi, R. ;

Massidda, B. ;

Distante, V. ;

Amadori, D. ;

Sismondi, P. .

ANNALS OF ONCOLOGY, 2006, 17 :VII10-VII14

[8] Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study [J].

Boccardo, F ;

Rubagotti, A ;

Amoroso, D ;

Mesiti, M ;

Romeo, D ;

Caroti, C ;

Farris, A ;

Cruciani, G ;

Villa, E ;

Schieppati, G ;

Mustacchi, G .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (22) :4209-4215

[9] Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial [J].

Boccardo, F ;

Rubagotti, A ;

Puntoni, M ;

Guglielmini, P ;

Amoroso, D ;

Fini, A ;

Paladini, G ;

Mesiti, M ;

Romeo, D ;

Rinaldini, M ;

Scali, S ;

Porpiglia, M ;

Benedetto, C ;

Restuccia, N ;

Buzzi, F ;

Franchi, R ;

Massidda, B ;

Distante, V ;

Amadori, D ;

Sismondi, P .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5138-5147

[10] Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma - Pooled analysis of 2 consecutive trials [J].

Boccardo, Francesco ;

Rubagotti, Alessandra ;

Aldrighetti, Daniela ;

Buzz, Franco ;

Cruciani, Giorgio ;

Farris, Antonio ;

Mustacchi, Giorgio ;

Porpiglia, Mauro ;

Schieppati, Giorgio ;

Sismondi, Piero .

CANCER, 2007, 109 (06) :1060-1067

← 1 2 3 4 5 6 7 8 9 →